In addition, RECQL4 is considered a potential molecular target for cancer therapy given that it correlates with a stem cell phenotype,6,7 and its overexpression has been observed to confer resistance to chemotherapy regimens in preclinical settings, including glioma.8–10. This evidence concerns the gene RECQL4 and central nervous system cancer.